Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tuberculosis sequelae: pathophysiological aspect (ventilation)].

M Ohi1, K Chin, T Tsutsui

  • 1Department of Clinical Physiology, Chest Disease Research Institute, Kyoto, Japan.

Kekkaku : [Tuberculosis]
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy.

ESMO gastrointestinal oncology·2026
Same author

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer.

ESMO gastrointestinal oncology·2026
Same author

The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy.

ESMO gastrointestinal oncology·2026
Same author

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma.

ESMO gastrointestinal oncology·2026
Same author

Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.

ESMO gastrointestinal oncology·2026
Same author

Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice.

ESMO gastrointestinal oncology·2026

Tuberculosis sequela patients exhibit higher hypercapnia than COPD patients. Chest Negative Pressure Ventilation (CNPV) effectively improves ventilation in tuberculosis sequela patients while awake, but its efficacy diminishes during sleep.

Area of Science:

  • Pulmonary Medicine
  • Respiratory Physiology
  • Sleep Medicine

Background:

  • Patients with tuberculosis sequela often experience higher PaCO2 levels compared to those with chronic obstructive lung disease (COLD).
  • Severe hypoventilation in hypercapnic patients necessitates interventions to prevent respiratory muscle fatigue and sleep-disordered breathing.

Observation:

  • This study investigated Chest Negative Pressure Ventilation (CNPV) in nine patients with hypercapnic chronic respiratory failure due to tuberculosis sequela.
  • Monitoring included transcutaneous PCO2 (PtcCO2) and Respiratory Inductance Plethysmography (RIP) during awake and sleep states.

Findings:

  • CNPV generated larger tidal volumes during mouth breathing (504 mL) than nose breathing (438 mL) in the awake state.
  • In the awake state, CNPV improved oxygen saturation to 95.7% and reduced PtcCO2 to 42.7 Torr.

Related Experiment Videos

  • During Non-REM sleep, CNPV maintained awake PtcCO2 levels, indicating partial effectiveness.

    • Implications:

    • Chest Negative Pressure Ventilation (CNPV) demonstrates effectiveness in improving ventilation for tuberculosis sequela patients in the awake state.
    • Further research is needed to optimize CNPV for sustained efficacy during sleep in these patients.